Antiviral peptides with specific broad antiviral activities could be considered as an additional potent therapeutic option for HIV/HCV co-infected patients. Incorporation of antiviral peptides into polyion complex micelles provides a valuable modality to minimize peptide degradation and toxicity, and increase the bioavailability. A structural cationic analog of amphiphatic a-helical peptide derived from the membrane anchor domain of HCV NS5A protein with dual anti-HIV-1 and anti-HCV activity was incorporated into polyion complexes with anionic block copolymers of poly(ethylene glycol) and poly(amino acid). The resulting antiviral peptide nanocomplexes (APN) were ca. 30 to 40 nm in size, stable in physiological conditions (pH, ionic strength) and retained virocidal activity. In vivo data demonstrated that APN are not toxic to animals and are able to suppress HIV viral replication.

Antiviral peptide nanocomplexes as novel therapeutic modality

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.